Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients

INTRODUCTION: From a series of radiolabelled cholecystokinin (CCK) and gastrin analogues, (111)In-CP04 ((111)In-DOTA-(DGlu)(6)-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH(2)) was selected for further translation as a diagnostic radiopharmaceutical towards a first-in-man study in patients with medullary thyroid c...

Descripción completa

Detalles Bibliográficos
Autores principales: Maina, Theodosia, Konijnenberg, Mark W., KolencPeitl, Petra, Garnuszek, Piotr, Nock, Berthold A., Kaloudi, Aikaterini, Kroselj, Marko, Zaletel, Katja, Maecke, Helmut, Mansi, Rosalba, Erba, Paola, von Guggenberg, Elisabeth, Hubalewska-Dydejczyk, Alicja, Mikolajczak, Renata, Decristoforo, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948680/
https://www.ncbi.nlm.nih.gov/pubmed/27185299
http://dx.doi.org/10.1016/j.ejps.2016.05.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948680/
https://www.ncbi.nlm.nih.gov/pubmed/27185299
http://dx.doi.org/10.1016/j.ejps.2016.05.011

Ejemplares similares